Ace imports of drugs down 50%! The third batch of popular discussion varieties also reduced prices, paving the way for collection?

Medicines Network June 3, June 1, Liaoning Province announced "on the implementation of dotlave sodium tablets and other three drugs active price reduction results notice", GSK, Zhengda Tianjing, China and the United States East China Pharmaceutical 3 enterprises produced 3 drugs to apply for active price reductionJudging from the results of the price reduction, GSK's ViiV Health Company's Dottilawi sodium tablets (50mg) fell from 1980 yuan to 980 yuan, a reduction of up to 50%; mg) fell 12.65 percent from 996 yuan to 870 yuan, while U.S.-China East Pharmaceuticals' injection dattomycin (0.5g) fell nearly 20 percent from 1,601 yuan to 1,290 yuanAce import drug price reduction is not soft
whether in the national collection, or health insurance negotiations, the original research drugs, imported drugs to reduce prices more and more, this trend of price reduction is spreadingThis time in Liaoning actively significantly reduce the price of dotlavsna tablets is GSK's ace anti-HIV drugs, ranked fourth in the global top sales of anti-HIV drugsAccording to Minenet, global sales of Dothilavs in 2018 were $2.229 billion, up 16.76 percent year-on-yearData show that in 2018 the global anti-HIV drug market has reached the size of $34 billion, the annual compound growth rate of more than 8%, Top 15 anti-HIV drug market reached more than 24 billion U.SdollarsNew drugs are growing faster, and the global market for anti-HIV drugs is expected to exceed $45 billion by 2023Specifically to China, china's CDC data show that the number of people infected with HIV in China increased from 809,000 in 2013 to 1.25 million in 2018, with a COMPOUND annual growth rate of 9.1%, exceeding the global averageChina's anti-HIV drug market is small, with a high growth spaceData show that in 2018, China's anti-HIV drug market reached 2 billion yuan, with a compound annual growth rate of 21%China's anti-HIV virus drug field to the country free supply-led market, in the new compound, long-acting drugs for clinical characteristics, as well as the promotion of health insurance policies, anti-HIV drugshospitalmarket will usher in rapid developmentAt present, the global anti-HIV drug market competition pattern is more concentrated, Gilead and GSK has been the field of the two largest market share of the two enterprises Among them, Gilead market share is close to 50%, dominant, its 4-in-1 new drug Genvoya sales of the highest, occupy the top of the market GSK, with dotlav-based compound sofhers, took the 2nd and 4th place in the anti-HIV drug market, and led the way with Gilead They were followed by Johnson and Johnson and Mershadon 　　With the acceleration of global research and development of anti-HIV drugs, the update iteration of the HIV drug market is becoming more and more obvious In the industry's view, foreign companies have different product lifecycle management strategies for different products For highly competitive mature products, some of the original drugs abandoned the price war in favor of brand marketing; 　　Or to pave the way for the collection in the original research drugs to join the tide of price reduction, with the intensification of competition, domestic enterprises on the price adjustment of products more proactive 　　In Liaoning market, Zhengda Tianqing took the initiative to reduce the azastine injection (100mg) to 870 yuan It is understood that azastine is suitable for the treatment of all subtypes of bone marrow hyperplasia syndrome, and has the qualification of rare disease treatment drugs At present, listed enterprises have Baxter, Zhengda Tianqing Pharmaceutical Group and Sichuan Huiyu 3 　　The original research manufacturer of Azathin is a new base, with global sales of US$594 million in 2018 In 2018, the product sold 8.48 million yuan in China's urban public hospitals, county-level public hospitals, and western and township hospitals in urban communities ,0yanet data show 　　At present, injection with azastine evaluation enterprises including Zhengda Tianqing and Sichuan Huiyu Pharmaceuticals, there are more than a dozen enterprises are also in the layout, this variety has also been industry speculation or a large probability of being selected in the third batch of national collection 　　In terms of price, at the end of September 2019, Zhengda Sun's injection of azastine was approved at a price of 996 yuan According to Jilin Province issued "on the public anti-cancer drug list (first batch), blood products, insulin and the agreement period of the state to negotiate generic drugs to add the price limit of the network, Sichuan Huiyu's hanging network limit price is 999 yuan Zhengda Tianqing this move to take the initiative to reduce prices or to actively open up the market, there are industry analysis is to set the way 　　Influenced by policy and market, in the overall drug prices continue to decline in the environment, there may be more and more enterprises choose to take the initiative to reduce prices, more active market layout